Skip to main content

Table 1 Patient characteristics

From: Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

Characteristic

 

Number = 121

%

Menopausal status

Premenopausal

60

49.6

Postmenopausal

61

50.4

Clinical staging

IIA

19

15.7

IIB

34

28.1

IIIA

40

33.1

IIIB

8

6.6

IIIC

20

16.5

Clinical staging primary tumor

cT1-2

52

43.0

cT3-4

69

57.0

Clinical staging nodes

cN0

39

32.2

cN1

36

29.8

cN2-3

46

38.0

Tumor type

Ductal invasive

113

93.4

Lobular invasive

5

4.1

Other

3

2.5

Tumor grade

GI

7

5.8

GII

39

32.2

GIII

61

50.4

Unknown

14

11.5

Hormone-sensitivity

Negative

39

32.2

Positive

80

66.1

No data

2

1.7

HER2 overexpression

Negative

87

71.9

Positive

29

24.0

Unknown

5

4.1

Triple negative

No

90

74.4

Yes

26

21.5

Unknown

5

4.1

IHC subtype

ER+ and/or PR+ and HER2-

61

50.4

ER+ and/or PR+ and HER2+

16

13.2

ER- and PR- and HER2+

13

10.7

ER- and PR- and HER2-

26

21.5

Non classifiable

5

4.1

Chemotherapy regimen

AC x 4 – Docetaxel x 4

97

80.2

Sequential anthracyclines-paclitaxel

10

8.3

Non anthracycline

2

1.7

Non anthracycline-taxane

4

3.3

Concomitant anthracyclines–taxane

8

6.6

Trastuzumab treatment

No

99

81.8

Neoadjuvant

17

14.0

Adjuvant

5

4.1

Local treatment

Mastectomy

67

55.3

Breast conservation surgery (BCT)

53

43.8

  1. ER, estrogen receptor, HER2, human epidermal growth factor receptor 2, IHC, immunohistochemistry; PR, progesterone receptor.